Sunshine Biopharma (NASDAQ:SBFM) Stock Rating Upgraded by Wall Street Zen

Sunshine Biopharma (NASDAQ:SBFM) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a report issued on Saturday.

Several other research firms have also recently weighed in on SBFM. Zacks Research upgraded Sunshine Biopharma to a “hold” rating in a research note on Wednesday, May 27th. Weiss Ratings lowered Sunshine Biopharma from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Sunshine Biopharma has an average rating of “Hold” and a consensus price target of $70.00.

Sunshine Biopharma Stock Performance

Shares of Sunshine Biopharma stock opened at $1.15 on Friday. The company has a 50 day moving average of $1.82 and a 200-day moving average of $6.86. Sunshine Biopharma has a 1-year low of $1.10 and a 1-year high of $24.30. The company has a market cap of $575,000.00, a PE ratio of -0.11 and a beta of 1.17.

Sunshine Biopharma (NASDAQ:SBFM) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.05. The business had revenue of $9.26 million for the quarter, compared to analyst estimates of $8.70 million. Sunshine Biopharma had a negative net margin of 17.94% and a negative return on equity of 26.36%. Research analysts forecast that Sunshine Biopharma will post -6.3 earnings per share for the current year.

Hedge Funds Weigh In On Sunshine Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new stake in Sunshine Biopharma in the fourth quarter valued at approximately $29,000. Two Sigma Investments LP bought a new stake in shares of Sunshine Biopharma during the third quarter worth $32,000. Finally, Citadel Advisors LLC increased its holdings in shares of Sunshine Biopharma by 23.1% during the third quarter. Citadel Advisors LLC now owns 78,087 shares of the company’s stock worth $116,000 after buying an additional 14,656 shares in the last quarter. Institutional investors own 41.98% of the company’s stock.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies.